alzheimer semaglutide evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and Associations of semaglutide with first‐time

Participants who experienced significant nausea did not lose more weight than those with minimal side effects

Its been found that gut microbiota dysbiosis (aka an imbalance with the healthy microorganisms that live in the gut affecting gut health) plays a factor in the GLP-1 resistance in individuals with Type 2 Diabetes

Achieving a healthy weight is complex and multifaceted

In trials on its cardiovascular effects in high-risk patients, it was reported to lower the occurrence of major adverse cardiovascular events (MACE) [11]

By stimulating insulin secretion and suppressing glucagon release, semaglutide helps regulate blood sugar levels, reducing the risk of hyperglycemia and its associated complications